

Guide to Using Your Pillcheck

Welcome to your Pillcheck pharmacogenetic test results! They show how your DNA affects your response to many prescription medications. Your results can help determine safer, more effective medications and dosages to fit your unique genetic profile. They can also provide peace of mind that medications you're currently taking are the right ones for you.

There are four parts to your Pillcheck results:





1. **Summary of Your Test** - for you to learn which medications you have a higher risk of side effects or poor response
2. **Information for Specialists** - your genetic profile and test details for healthcare providers
3. **Personalized Results for You** - use it for any medications you may need in the future
4. **Pharmacist Opinion Letter** - your pharmacist action plan with personalized treatment recommendations. Take this to your doctor to discuss (available now as a separate document in your account)

How to use the Summary of Your Test

The colour-coded summary of your Pillcheck shows your predicted risk for all medications included on the test. These are key medical facts about you that your doctor should consider. Use it to check prescriptions you're taking now and for any new medication being considered in the future. The summary shows which medications may be right for you and which ones should be used with extra caution. Click any drug name in the summary to see your detailed test results for it.

You may not recognize the names of the drugs in your report because they are 'generic' drug names. If you check the label of your prescriptions, you should be able to find the generic name and then find it in the report.

Meaning of the symbols in your report

-  Normal drug metabolism and response. No additional dose adjustment needed.
-  Altered drug metabolism. Can affect clinical response, may require dose adjustment or increased monitoring.
-  Substantially altered drug metabolism. Requires physicians to adjust dose or consider alternative medications.
-  Uncertain activity requires caution in drug use. A rare or indeterminate combination of genetic markers is present.

What to do with your Pillcheck Results

- Bring a copy of your Pharmacist Opinion Letter to your doctor or pharmacist (either print or bring on a mobile device).
- Discuss your Pillcheck results with your doctor to improve efficacy and safety of your treatment plan.
- Since your genetic make-up doesn't change, be sure to consult your Pillcheck Report whenever you are prescribed new medications.
- You can grant your doctor/pharmacist online access to your full Pillcheck report by sending us your provider's name, email, phone, and fax numbers.

You or your provider can contact us at support@pillcheck.ca, 1-877-409-3629, or contact the pharmacist listed on your Pharmacist Opinion Letter if you have any questions about your Pillcheck. More information for healthcare providers can be found at www.pillcheck.ca/providers.

Sample ID:
Report Date:

TEST_SAMPLE
Apr 04, 2022 2:44 PM EST






Other Notes

- It's possible that your report will indicate there are no issues with any of the medications you're taking (for example, they're all in the Green category), yet you may still feel you are having issues. There may be other factors involved in how you respond to medications (such as your medical condition, age, liver and kidney function, etc.). Your doctor is the best person to discuss this with.
- Although Pillcheck is a comprehensive pharmacogenetic test, not all medications are listed on the report, even ones you may currently be taking. This is because not all drugs can be assessed by pharmacogenetics or there is not enough clinical information yet to report on certain medications.
- We'll update your report as new information on medications become available. We'll contact you by email to let you know when your report is updated.

DO NOT CHANGE ANY MEDICATIONS OR DOSAGE PRIOR TO CONSULTING YOUR PHYSICIAN OR PHARMACIST, WHO SHOULD DETERMINE AN APPROPRIATE DOSE. Please note, this report is intended for educational purposes only and does not constitute medical advice.

SAMPLE REPORT

Summary of Your Test

TREATMENT AREA	 USE WITH INCREASED CAUTION - CONSIDER ALTERNATIVES	 USE WITH CAUTION - MORE FREQUENT MONITORING	 USE AS DIRECTED - STANDARD PRECAUTION
Analgesics	Buprenorphine Celecoxib Codeine Flurbiprofen Ibuprofen Lornoxicam Meloxicam Oxycodone Piroxicam Tenoxicam Tolperisone Tramadol and acetaminophen	Diclofenac Hydrocodone Lofexidine Nabumetone	Carisoprodol Fentanyl Hydromorphone Methadone Morphine Naloxone Naltrexone Naproxen Propofol
Antibacterial	Dapsone Nitrofurantoin		
Antiemetics	Aprepitant Dronabinol Fosaprepitant Meclizine	Dolasetron Ondansetron Palonosetron Tropisetron	
Antifungal	Itraconazole Posaconazole	Terbinafine	Voriconazole
Antiviral	Fosamprenavir	Maraviroc	Atazanavir Dolutegravir Efavirenz Nevirapine Raltegravir

Information for Specialists

Customer Genetic Profile

Biomarker	Value	Biomarker	Value
ABCG2	G/T	DPYD	*1/*1
ADRB2	G/G	F2	A/A
CYP1A2	*1A/*1A	F5	C/C
CYP2B6	*1/*1	G6PD	Nashville/Nashville
CYP2C19	*1/*1	NUDT15	*1/*1
CYP2C8	*1A/*1A	OPRM1	A/A
CYP2C9	*3/*3	SLCO1B1	*5/*5
CYP2D6	*1/*1	TPMT	*1/*2
CYP2D6 CNV	3N	UGT1A1	*1/*1
CYP3A4	*6/*6	UGT2B15	A/C
CYP3A5	*1/*3	VKORC1	T/T

TEST_SAMPLE|2022-04-04 18:44:47|1d6e297298bf42708455be2e73e863c3|Pillcheck FSQS February 2021|Pillcheck FSQS v.3|db.228|rep.228|det.228

Technology used in the testing process

Gene	Alleles Tested
ABCG2	rs2231142 G/T
ADRB2	rs1042713 G/A
CYP1A2	*1E, *1F, *1J, *1K, *6, *7, *8, *15
CYP2B6	*2, *5, *6, *7, *8, *13, *16, *22, *34
CYP2C19	*2, *3, *4, *6, *8, *10, *17
CYP2C8	*2, *3, *4
CYP2C9	*2, *3, *5, *6, *8, *9, *11, *12, *27
CYP2D6	*3, *4, *5, *6, *7, *10, *17, *29, *41, *64, *69, *82
CYP3A4	*3, *6, *11, *12, *16, *17, *18, *19, *22
CYP3A5	*2, *3, *6
DPYD	*2A, *4, *5, *6, *9A, c.2846A>T
F2	rs1799963 G/A
F5	rs6025 C/T
G6PD	Malaga, Mediterranean, Aveiro, Iowa, Nashville, Santiago de Cuba, Kaiping
NUDT15	*2, *5
OPRM1	rs1799971 A/G
SLCO1B1	*1B, *5, *9, *15, *31
TPMT	*2, *3A, *8
UGT1A1	*6, *27, *80
UGT2B15	rs1902023 A/C
VKORC1	rs9923231 C/T

Technology: Genotyping was performed using the Applied Biosystems™ QuantStudio™ platform and this report is powered by [Pillcheck technology](#).

Limitations: This test will not detect all known mutations that result in altered gene activity. *1 or wild-type alleles are reported by default if those listed were not detected. IND values are conservatively assigned to alleles that could not be determined with complete certainty. Only listed mutations are tested for and absence of a detected mutation does not rule out the possibility of sensitivity to a specific drug due to the presence of other mutations or other environmental factors.

Additional genetic testing by sequencing might uncover other functional variations that the individual may carry that also affect the medication response, but were not detected in this analysis.

Drug Page Index

A	9	O	41
B	13	P	42
C	14	Q	46
D	19	R	47
E	23	S	49
F	25	T	51
G	29	U	56
H	30	V	56
I	30	W	58
K	32	Z	58
L	32		
M	35		
N	39		

Personalized Results for You

Acenocoumarol

General drug info:
<https://portal.pillcheck.net/medication/E4C8>

Use 50% of the standard initial dose and more frequent monitoring of the INR. Consider alternative treatment with Factor Xa inhibitors.

Biomarker	Value	Interpretation	Level of evidence
CYP2C9	*3/*3	Poor metabolizer	CPIC B
VKORC1	T/T	Low Vitamin K production	CPIC B

Alirocumab

General drug info:
<https://portal.pillcheck.net/medication/Y6X4>

The variation you carry in the SLCO1B1 gene indicates that you have a high myopathy risk and will be statin-intolerant. Consider treatment with PCSK9 inhibitors.

Biomarker	Value	Interpretation	Level of evidence
SLCO1B1	*5/*5	Poor function	FDA

! Cilostazol

General drug info:
<https://portal.pillcheck.net/medication/E4H3>

Increased metabolism of cilostazol as compared to CYP3A5 non-expressors, possibly reducing clinical response. Variations in CYP2C19 and CYP3A4 may also influence metabolism of cilostazol. Consider discontinuation or dosage reduction for cilostazol if coadministration with CYP3A4 or CYP2C19 inhibitors, or if used in poor CYP2C19 or poor CYP3A4 metabolizers.

Biomarker	Value	Interpretation	Level of evidence
CYP3A5	*1/*3	Intermediate metabolizer	FDA

! Cisplatin

General drug info:
<https://portal.pillcheck.net/medication/V6K9>

Decreased drug clearance may increase risk of cisplatin-induced ototoxicity, renal toxicity and other side effects. Consider starting with reduced cisplatin doses. Allow 2-4 weeks to reach steady state after each dose adjustment.

Biomarker	Value	Interpretation	Level of evidence
TPMT	*1/*2	Intermediate metabolizer	FDA

✓ Citalopram

General drug info:
<https://portal.pillcheck.net/medication/Y9T8>

Normal metabolism of citalopram is anticipated; standard dosing and precautions are recommended.

Biomarker	Value	Interpretation	Level of evidence
CYP2C19	*1/*1	Normal metabolizer	CPIC A

✓ Clobazam

General drug info:
<https://portal.pillcheck.net/medication/L4M2>

Normal metabolism of Clobazam is anticipated; standard dosing and precautions are recommended. Titrate according to weight. If necessary and based upon clinical response, an additional titration to the maximum dose (20 mg/day or 40 mg/day, depending on the weight group) may be started on day 14.

Biomarker	Value	Interpretation	Level of evidence
CYP2C19	*1/*1	Normal metabolizer	CPIC C

! Clomipramine

General drug info:
<https://portal.pillcheck.net/medication/A8W4>

Avoid the use of amitriptyline, clomipramine, doxepin, imipramine, trimipramine due to significantly enhanced clearance and reduced response.

Biomarker	Value	Interpretation	Level of evidence
CYP2C19	*1/*1	Normal metabolizer	CPIC A
CYP2D6 CYP2D6 CNV	*1/*1 3N	Ultrarapid metabolizer	CPIC A